Reduction of scrapie incubation time in mice and hamsters by a single injection of methanol extraction residue of bcg

The Effects of Immune System Modulation on Prion Disease Susceptibility and Pathogenesis

Prion diseases are a unique group of infectious chronic neurodegenerative disorders to which there are no cures. Although prion infections do not stimulate adaptive immune responses in infected individuals, the actions of certain immune cell populations can have a significant impact on disease pathogenesis. After infection, the targeting of peripherally-acquired prions to specific immune cells in the secondary lymphoid organs (SLO), such as the lymph nodes and spleen, is essential for the efficient transmission of disease to the brain. Once the prions reach the brain, interactions with other immune cell populations can provide either host protection or accelerate the neurodegeneration. In this review, we provide a detailed account of how factors such as inflammation, ageing and pathogen co-infection can affect prion disease pathogenesis and susceptibility. For example, we discuss how changes to the abundance, function and activation status of specific immune cell populations can affect the transmission of prion diseases by peripheral routes. We also describe how the effects of systemic inflammation on certain glial cell subsets in the brains of infected individuals can accelerate the neurodegeneration. A detailed understanding of the factors that affect prion disease transmission and pathogenesis is essential for the development of novel intervention strategies.

Intraperitoneal infection with scrapie is established within minutes of injection and is non-specifically enhanced by a variety of different drugs

Single intraperitoneal (i.p.) doses of 16 different drugs were given to mice 2 h before injecting scrapie i.p. Scrapie was injected as serial ten-fold dilutions of standard inocula and the effective titres obtained were used as a measure of the relative efficiency of infection in treated compared to saline injected mice. Despite the wide variety of drugs tested, most of them increased, non-specifically, the efficiency of infection by 0.6 to 2.1 log10 i.p. LD50 units (i.e., 4 to 126-fold), but only when both drug and scrapie were given i.p. The effect was greatest with a 2 h or a 6 h interval suggesting an involvement either of resident peritoneal cells or of elicited cells such as polymorphonuclear neutrophils. There was no increase in the efficiency of infection after intervals of 2 or 7 days when induced macrophages would predominant. The reverse sequence of injections (scrapie-0.5 h-drug) had no effect despite the persistence of high scrapie titre in the peritoneum at the time of drug injection. However, the effect was restored by a second injection of scrapie in the sequence, scrapie-drug-scrapie. It is concluded that scrapie infection is established within minutes of injection but much of the inoculum is associated with peritoneal cells which are irrelevant to pathogenesis. Drugs may enhance the infection of relevant peritoneal cells or their targeting to the visceral lymphoreticular tissues where early replication takes place.

Ionising radiation has no influence on scrapie incubation period in mice

Scrapie has an early non-clinical stage when replication of agent occurs in lymphoreticular organs. Whole-body irradiation failed to alter the incubation or neuropathology of the disease. Many experiments were carried out with different strains of scrapie agent and host, doses and timing of irradiation. The results suggest that mitotically quiescent cells are involved in agent replication.

Isolation and characterization of macrophages from scrapie-infected mouse brain

We have isolated and characterized a population of brain macrophages from normal and scrapie-infected mice. The cells are phagocytic, possess Fc-IgG receptors, Mac-1 surface antigen and proliferate in the presence of macrophage colony stimulating factor. They resemble microglia in that they have a plasmalemmal distribution of the enzyme nucleoside diphosphatase, a property tht is characteristic of microglia in situ. In two of the three combinations of scrapie agent and mouse strain examined, the number of brain macrophages was several fold higher than in normal control mice. The increase was not observed in mice infected intraperitoneally or in control mice inoculated with normal brain homogenate. The increase is detectable as early as 3-5 weeks postinoculation. The agent/host combination that failed to show an increase in brain macrophages is one that develops large numbers of amyloid plaques. These observations suggest that these cells are closely associated with the scrapie pathogenic process in the CNS. The failure of these cells to increase in the plaque forming model of scrapie disease also suggests that they play a role in the control of CNS amyloidogenesis.

Pathogenesis of mouse scrapie: distribution of agent in the pulp and stroma of infected spleens

Fourteen spleens were collected from mice infected with the 139A strain of scrapie, at a time when the concentration of agent in spleen was at a plateau. Scrapie infectivity was present in both the pulp and stromal fractions, but the concentration in stroma was about 10 times greater than that in pulp. On average, 1000 pulp cells were required to give 1 LD50 unit of scrapie infectivity. Linear regression analysis of data from 64 mouse spleens showed that the total infectivity correlated with tissue weight (P less than 0.001). The titres of the 14 stromal fractions were significantly correlated with whole spleen weight (P less than 0.02) and with the weight of stroma (P less than 0.02), but not with pulp weight. Hence, the titres in the isolated stroma probably reflect those of the stroma in vivo. In contrast, there was no correlation between total pulp titre and spleen weight, pulp weight or pulp cell number. Moreover, gentle washing of pulp cells removed about 80% of the total infectivity. This suggests that much of the pulp titre is adventitiously associated with cells and is in fact agent released from damaged stroma.

The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection

The effects of up to 12 daily doses of HPA-23 (ammonium 5-tungsto-2-antimoniate) on scrapie were studied using five experimental models of the disease, some with widely different incubation times. Treatment of animals with HPA-23, starting just before injecting scrapie, produced survivors. In some experiments, animals were fully protected against several hundred infectious units of scrapie. Treatment of animals after infection was far less effective. Prolonging the treatment for several weeks was no more effective than treating for a few days. In a very long incubation model of scrapie, the course of 12 daily doses of HPA-23 represented less than 3 per cent of the total incubation period. HPA-23 may interact with certain cells of the lymphoreticular system, preventing infection and, perhaps, the early replication of agent.